On Wednesday, RBC Capital maintained its Sector Perform rating on Nevro Corp (NYSE:NVRO) but reduced the stock's price target significantly to $7.00 from the previous $16.00.
This change comes after the company reported a second-quarter performance that fell short in sales but exceeded earnings per share (EPS) expectations. Nevro also revised its full-year 2024 revenue forecast downward by 8.5%, now anticipating a year-over-year decline of 5-6%, which translates to revenues between $400 million and $405 million.
The management of Nevro cited challenges in the U.S. spinal cord stimulation (SCS) market, where earlier line therapies are gaining traction and increasing competitive pressures. These factors are expected to persist into the second half of 2024. The disappointing quarterly results and the projection of continued market difficulties have led to diminished visibility for the company's financial outlook.
The lowered revenue guidance reflects the company's struggles amid a competitive landscape and market softness. The updated forecast indicates a shift in the company's expected performance, taking into account the current market conditions that are influencing Nevro's operations.
The company is navigating a tough SCS market, which has led to the revised expectations and strategic reassessments reflected in the updated guidance and RBC Capital's price target adjustment.
In other recent news, Nevro Corp has been the subject of several analyst adjustments following mixed financial results. Nevro's sales fell short of expectations, leading to a downgrade from both JMP Securities and JPMorgan (NYSE:JPM). Despite strategic efforts including the launch of new spinal cord stimulation indications and acquisitions, Nevro now anticipates a decline in sales for the second half of 2024 and a larger EBITDA loss.
Baird has also trimmed its price target for Nevro, citing concerns about the company's short-term growth prospects and market share recovery. Similarly, BofA Securities lowered its stock price target for Nevro following the company's first-quarter results, which showed a mix of strengths and challenges.
On a positive note, Nevro Corp reported an 8% organic growth and a significant 73% year-over-year increase in positive free cash flow. Nevro Corp has also raised its full-year 2024 outlook, expecting gross revenue to be between $937 and $942 million, and adjusted earnings per share to be between $5.05 to $5.11.
These recent developments reflect the financial dynamics of Nevro Corp and the differing perspectives of financial analysts.
InvestingPro Insights
As Nevro Corp (NYSE:NVRO) confronts a challenging market, recent data from InvestingPro provides a deeper financial perspective on the company. With a market capitalization of $319.17 million, Nevro's financial health is a mix of strengths and concerns. Notably, the company holds more cash than debt, indicating a solid balance sheet. However, it is important to recognize their rapid cash burn, which is a point of caution for investors. Additionally, three analysts have revised their earnings forecasts downward for the upcoming period, suggesting a cautious outlook on the company's near-term profitability.
InvestingPro data also highlights that Nevro's stock has experienced significant pressure, with a six-month price total return of -49.45%. This aligns with the recent price target adjustment from RBC Capital. Despite the setbacks, it's worth noting that Nevro's liquid assets exceed its short-term obligations, providing some financial flexibility. The company does not pay a dividend, which could be a factor for income-focused investors to consider.
For those seeking additional insights on Nevro Corp, InvestingPro offers more tips, including an analysis of the company's profitability over the last twelve months and its stock performance over various time frames. With additional tips available on InvestingPro, investors can gain a comprehensive view of Nevro's financial standing and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.